Gretai:4130

NaviFUS Launches Neuronavigation-guided Clinical Trial to Open the Blood-Brain-Barrier for Combination FUS-Bevacizumab Therapy in rGBM Patients

TAIPEI, Sept. 11, 2020 /PRNewswire/ -- Genovate Biotech (TPEX:4130) subsidiary andTaiwan-based focused ultrasound (FUS) manufacturer NaviFUS Corporation is pleased to announce the start of its clinical trial (NCT04446416) for the combination of FUS plus bevacizumab therapy. Researchers at Linkou ...

2020-09-11 20:55 3946